Tumour necrosis factor (tnf)alpha-308 g/g promoter polymorphism and tnf alpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis

dc.date.accessioned2017-03-23T17:48:46Z
dc.date.available2017-03-23T17:48:46Z
dc.date.created2017-03-23T17:48:46Z
dc.date.issued2006
dc.identifier0300-9742
dc.identifierhttp://hdl.handle.net/10533/178236
dc.identifier1040439
dc.identifierWOS:000243529000003
dc.languageeng
dc.publisherTAYLOR & FRANCIS
dc.relationhttps://doi.org/10.1080/03009740600904284
dc.relation10.1080/03009740600904284
dc.relationinfo:eu-repo/grantAgreement/Fondecyt/1040439
dc.relationinfo:eu-repo/semantics/dataset/hdl.handle.net/10533/93477
dc.relationinstname: Conicyt
dc.relationreponame: Repositorio Digital RI2.0
dc.relationinstname: Conicyt
dc.relationreponame: Repositorio Digital RI2.0
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleTumour necrosis factor (tnf)alpha-308 g/g promoter polymorphism and tnf alpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis
dc.typeArticulo


Este ítem pertenece a la siguiente institución